Julia C Dombrowski1,2, Michael R Wierzbicki3, Lori M Newman4, Jonathan A Powell3, Ashley Miller5, Dwyn Dithmer2, Olusegun O Soge6, Kenneth H Mayer7,8. 1. Department of Medicine, University of Washington, Seattle, Washington, USA. 2. HIV/STD Program, Public Health-Seattle & King County, Seattle, Washington, USA. 3. The Emmes Company, LLC, Rockville, Maryland, USA. 4. Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA. 5. FHI 360, Durham, North Carolina, USA. 6. Departments of Medicine and Global Health, University of Washington, Seattle, Washington, USA. 7. Fenway Health, Boston, Massachusetts, USA. 8. Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Azithromycin and doxycycline are both recommended treatments for rectal Chlamydia trachomatis (CT) infection, but observational studies suggest that doxycycline may be more effective. METHODS: This randomized, double-blind, placebo-controlled trial compared azithromycin (single 1-g dose) versus doxycycline (100 mg twice daily for 7 days) for the treatment of rectal CT in men who have sex with men (MSM) in Seattle and Boston. Participants were enrolled after a diagnosis of rectal CT in clinical care and underwent repeated collection of rectal swabs for nucleic acid amplification testing (NAAT) at study enrollment and 2 weeks and 4 weeks postenrollment. The primary outcome was microbiologic cure (CT-negative NAAT) at 4 weeks. The complete case (CC) population included participants with a CT-positive NAAT at enrollment and a follow-up NAAT result; the intention-to-treat (ITT) population included all randomized participants. RESULTS: Among 177 participants enrolled, 135 (76%) met CC population criteria for the 4-week follow-up visit. Thirty-three participants (19%) were excluded because the CT NAAT repeated at enrollment was negative. Microbiologic cure was higher with doxycycline than azithromycin in both the CC population (100% [70 of 70] vs 74% [48 of 65]; absolute difference, 26%; 95% confidence interval [CI], 16-36%; P < .001) and the ITT population (91% [80 of 88] vs 71% [63 of 89]; absolute difference, 20%; 95% CI, 9-31%; P < .001). CONCLUSIONS: A 1-week course of doxycycline was significantly more effective than a single dose of azithromycin for the treatment of rectal CT in MSM. CLINICAL TRIALS REGISTRATION: NCT03608774.
BACKGROUND: Azithromycin and doxycycline are both recommended treatments for rectal Chlamydia trachomatis (CT) infection, but observational studies suggest that doxycycline may be more effective. METHODS: This randomized, double-blind, placebo-controlled trial compared azithromycin (single 1-g dose) versus doxycycline (100 mg twice daily for 7 days) for the treatment of rectal CT in men who have sex with men (MSM) in Seattle and Boston. Participants were enrolled after a diagnosis of rectal CT in clinical care and underwent repeated collection of rectal swabs for nucleic acid amplification testing (NAAT) at study enrollment and 2 weeks and 4 weeks postenrollment. The primary outcome was microbiologic cure (CT-negative NAAT) at 4 weeks. The complete case (CC) population included participants with a CT-positive NAAT at enrollment and a follow-up NAAT result; the intention-to-treat (ITT) population included all randomized participants. RESULTS: Among 177 participants enrolled, 135 (76%) met CC population criteria for the 4-week follow-up visit. Thirty-three participants (19%) were excluded because the CT NAAT repeated at enrollment was negative. Microbiologic cure was higher with doxycycline than azithromycin in both the CC population (100% [70 of 70] vs 74% [48 of 65]; absolute difference, 26%; 95% confidence interval [CI], 16-36%; P < .001) and the ITT population (91% [80 of 88] vs 71% [63 of 89]; absolute difference, 20%; 95% CI, 9-31%; P < .001). CONCLUSIONS: A 1-week course of doxycycline was significantly more effective than a single dose of azithromycin for the treatment of rectal CT in MSM. CLINICAL TRIALS REGISTRATION: NCT03608774.
Authors: Christine M Khosropour; Julia C Dombrowski; Lindley A Barbee; Lisa E Manhart; Matthew R Golden Journal: Sex Transm Dis Date: 2014-02 Impact factor: 2.830
Authors: Brian Dodge; Barbara Van Der Pol; Michael Reece; David Malebranche; Omar Martinez; Gabriel Goncalves; Phillip Schnarrs; Ryan Nix; J Dennis Fortenberry Journal: Sex Health Date: 2012-05 Impact factor: 2.706
Authors: Jannie J van der Helm; Christian J P A Hoebe; Martijn S van Rooijen; Elfi E H G Brouwers; Han S A Fennema; Harold F J Thiesbrummel; Nicole H T M Dukers-Muijrers Journal: Sex Transm Dis Date: 2009-08 Impact factor: 2.830
Authors: Mary Elizabeth Sexton; Joseph J Baker; Keisuke Nakagawa; Ying Li; Rodney Perkins; Rebecca S Slack; Daniel C Baker; Brian Jucha; Sameer Arora; Michael W Plankey Journal: J Fam Pract Date: 2013-02 Impact factor: 0.493
Authors: Eric P F Chow; Shayne Camilleri; Christopher Ward; Sarah Huffam; Marcus Y Chen; Catriona S Bradshaw; Christopher K Fairley Journal: Sex Health Date: 2016-06 Impact factor: 2.706
Authors: William M Geisler; Jane S Hocking; Toni Darville; Byron E Batteiger; Robert C Brunham Journal: Clin Infect Dis Date: 2022-04-13 Impact factor: 9.079
Authors: Lindley A Barbee; Olusegun O Soge; Christine M Khosropour; Angela LeClair; Matthew R Golden Journal: J Clin Microbiol Date: 2022-05-05 Impact factor: 11.677
Authors: Christine M Khosropour; Julia C Dombrowski; Lucia Vojtech; Dorothy L Patton; Lee Ann Campbell; Lindley A Barbee; Michaela C Franzi; Kevin Hybiske Journal: Sex Transm Dis Date: 2021-12-01 Impact factor: 2.830
Authors: Barbara Van Der Pol; Max Chernesky; Charlotte A Gaydos; Edward W Hook; Ajith M Joseph; Katherine Christensen; Rodney Arcenas; Alexander Boutwell; Harold C Wiesenfeld; Stephanie N Taylor; Kenneth H Mayer; Matthew R Golden; Jeanne Moncada; Dan Jang; Julius Schachter Journal: J Clin Microbiol Date: 2021-11-03 Impact factor: 11.677
Authors: Laura Platt; Heather Elder; Ingrid V Bassett; Lauren Molotnikov; Monina Klevens; Erin O'Connor; Dylan Leach; Kathleen Roosevelt; Katherine Hsu Journal: J Prim Care Community Health Date: 2021 Jan-Dec
Authors: Nicole H T M Dukers-Muijrers; Ymke J Evers; Christian J P A Hoebe; Petra F G Wolffs; Henry J C de Vries; Bernice Hoenderboom; Marianne A B van der Sande; Janneke Heijne; Jeffrey D Klausner; Jane S Hocking; Jan van Bergen Journal: BMC Infect Dis Date: 2022-03-14 Impact factor: 3.090
Authors: Timothy W Menza; Stephen A Berry; Julie Dombrowski; Edward Cachay; Heidi M Crane; Mari M Kitahata; Kenneth H Mayer Journal: Open Forum Infect Dis Date: 2022-06-17 Impact factor: 4.423
Authors: Lindley A Barbee; Christine M Khosropour; Olusegun O Soge; James P Hughes; Micaela Haglund; Winnie Yeung; Matthew R Golden Journal: Clin Infect Dis Date: 2022-05-03 Impact factor: 20.999